A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma Clinical Trial

Official title:
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy

Status Completed

Clinical Trial Summary

The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Melanoma
Unresectable or Metastatic Melanoma

Clinical Trial Details

NCT number	NCT01721746
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 3
Start date	December 21, 2012
Completion date	December 29, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06359860` - A Study of ST-1898 for Unresectable or Metastatic Melanoma	Phase 1/Phase 2
Terminated	`NCT03993379` - PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors	Phase 2
Active, not recruiting	`NCT01844505` - Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)	Phase 3
Terminated	`NCT01810016` - NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma	Phase 1
Active, not recruiting	`NCT05783882` - Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma	Phase 3
Recruiting	`NCT04674683` - Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma	Phase 3